Patent ID: 7972627
Filing Date: 2011-07-05
Classification: A61K,A61L,A61P

Abstract:
1. A nasal pharmaceutical formulation comprising an aqueous suspension of a therapeutically effective amount of beclomethasone, wherein the formulation comprises beclomethasone dipropionate monohydrate equivalent to 0.042% w/w beclomethasone dipropionate, calculated on a dry basis, having the following particle size distribution profile: (i) about 10% of the beclomethasone particles have a particle size of less than 0.3 microns; (ii) about 25% of the beclomethasone particles have a particle size of less than 0.6 microns; (iii) about 50% of the beclomethasone particles have a particle size of less than 1.1 microns; (iv) about 75% of the beclomethasone particles have a particle size of less than 1.8 microns; and (v) about 90% of the beclomethasone particles have a particle size of less than 2.7 microns, and wherein the beclomethasone is suitable for intranasal administration to the nasal mucosa of an individual.